Skip to main content

PROTEINA C-REACTIVA MONOMERICA COMO BIOMARCADOR Y DIANA TERAPEUTICA DE LA DEGENERACION MACULAR ASOCIADA A LA EDAD

PI19/00265

•
Funding agency name Instituto de Salud Carlos III
Funding agency acronym ISCIII
Program Programa Estatal de Generación de Conocimiento y Fortalecimiento del Sistema Español de I+D+I
Subprogram Subprograma Estatal de Generación de Conocimiento
Call Proyectos de Investigación en Salud
Call year 2019
State Plan 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre FUNDACION PRIVADA CLINIC
Execution centre HOSPITAL CLINICO Y PROVINCIAL DE BARCELONA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

C-reactive protein-complement factor H axis as a biomarker of activity in early and intermediate age-related macular degeneration

  • Giralt, Lena
  • Figueras-Roca, Marc|||0000-0002-0548-0539
  • Eguileor, Beatriz De Luis
  • Romero, Barbara
  • Zarranz-Ventura, Javier|||0000-0003-2338-8143
  • Alforja, Socorro
  • Santiago, Francisca
  • Bolaños, Jennifer
  • Lozano, Francisco
  • Dotti-Boada, Marina
  • Sala-Puigdollers, Anna
  • Dura, Paula
  • Izquierdo-Serra, Jordi
  • Valero, Oliver|||0000-0003-0014-9916
  • Adan Civera, Alfredo|||0000-0002-0849-8814
  • Fonollosa, Alex
  • Molins, Blanca|||0000-0003-0941-9134
To determine and compare the serum levels of complement Factor H (FH), monomeric C-Reactive Protein (mCRP) and pentameric C-Reactive protein (pCRP) in patients with age-related macular degeneration (AMD) and to correlate them with clinical, structural and functional parameters. Cross-sectional observational study. One hundred thirty-nine individuals (88 patients and 51 healthy controls) from two referral centers were included and classified into three groups: early or intermediate AMD (n=33), advanced AMD (n=55), and age and sex matched healthy controls (n=51). Serum levels of FH, mCRP, and pCRP were determined and correlated with clinical and imaging parameters. Patients with intermediate AMD presented FH levels significantly lower than controls [186.5 (72.1-931.8) µg/mL vs 415.2 (106.1-1962.2) µg/mL; p=0.039] and FH levels <200 µg/mL were associated with the presence of drusen and pigmentary changes in the fundoscopy (p=0.002). While no differences were observed in pCRP and mCRP levels, and mCRP was only detected in less than 15% of the included participants, women had a significantly higher detection rate of mCRP than men (21.0% vs. 3.8%, p=0.045). In addition, the ratio mCRP/FH (log) was significantly lower in the control group compared to intermediate AMD (p=0.031). Visual acuity (p<0.001), macular volume (p<0.001), and foveal thickness (p=0.034) were significantly lower in the advanced AMD group, and choroidal thickness was significantly lower in advanced AMD compared to early/intermediate AMD (p=0.023). Intermediate AMD was associated in our cohort with decreased serum FH levels together with increased serum mCRP/FH ratio. All these objective serum biomarkers may suggest an underlying systemic inflammatory process in early/intermediate AMD patients.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

C-reactive protein isoforms as prognostic markers of COVID-19 severity

  • Molins, Blanca|||0000-0003-0941-9134
  • Figueras-Roca, Marc|||0000-0002-0548-0539
  • Valero, Oliver|||0000-0003-0014-9916
  • Llorenç, Víctor|||0000-0002-7375-1564
  • Romero-Vázquez, Sara|||0000-0002-2053-7230
  • Sibila, Oriol|||0000-0002-4833-6713
  • Adan Civera, Alfredo|||0000-0002-0849-8814
  • Garcia-Vidal, Carolina|||0000-0002-8915-0683
  • Soriano Viladomiu, Alex|||0000-0002-9374-0811
C-reactive protein (CRP), an active regulator of the innate immune system, has been related to COVID-19 severity. CRP is a dynamic protein undergoing conformational changes upon activation in inflammatory microenvironments between pentameric and monomeric isoforms. Although pentameric CRP is the circulating isoform routinely tested for clinical purposes, monomeric CRP shows more proinflammatory properties. Therefore, we aimed to determine the potential of monomeric CRP in serum as a biomarker of disease severity in COVID-19 patients (admission to intensive care unit [ICU] and/or in-hospital mortality). We retrospectively determined clinical and biological features as well as pentameric and monomeric CRP levels in a cohort of 97 COVID-19 patients within 72h of hospital admission. Patients with severe disease had higher levels of both pentameric and monomeric CRP. However, multivariate analysis showed increased mCRP but not pCRP to be independently associated to disease severity. Notably, mCRP levels higher than 4000 ng/mL (OR: 4.551, 95% CI: 1.329-15.58), together with number of co-morbidities, low lymphocyte count, and procalcitonin levels were independent predictors of disease severity in the multivariate model. Our results show the potential of mCRP levels as a marker of clinical severity in COVID-19 disease.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Activation of C-reactive protein proinflammatory phenotype in the blood retinal barrier in vitro, Implications for age-related macular degeneration

  • Romero-Vázquez, Sara|||0000-0002-2053-7230
  • Adan Civera, Alfredo|||0000-0002-0849-8814
  • Figueras-Roca, Marc|||0000-0002-0548-0539
  • Llorenç, Víctor|||0000-0002-7375-1564
  • Slevin, M.
  • Vilahur, Gemma|||0000-0002-2828-8873
  • Badimon, Lina|||0000-0002-9162-2459
  • Dick, Andrew D.
  • Molins, Blanca|||0000-0003-0941-9134
The retinal pigment epithelium (RPE) is considered one of the main targets of age-related macular degeneration (AMD), the leading cause of irreversible vision loss among the ageing population worldwide. Persistent low grade inflammation and oxidative stress eventually lead to RPE dysfunction and disruption of the outer blood-retinal barrier (oBRB). Increased levels of circulating pentameric C-reactive protein (pCRP) are associated with higher risk of AMD. The monomeric form (mCRP) has been detected in drusen, the hallmark deposits associated with AMD, and we have found that mCRP induces oBRB disruption. However, it is unknown how mCRP is generated in the subretinal space. Using a Transwell model we found that both pCRP and mCRP can cross choroidal endothelial cells and reach the RPE in vitro and that mCRP, but not pCRP, is able to cross the RPE monolayer in ARPE-19 cells. Alternatively, mCRP can originate from the dissociation of pCRP in the surface of lipopolysaccharide-damaged RPE in both ARPE-19 and primary porcine RPE lines. In addition, we found that the proinflammatory phenotype of mCRP in the RPE depends on its topological localization. Together, our findings further support mCRP contribution to AMD progression enhancing oBRB disruption.